Clinical Trials in Baltimore

Showing 5861-5880 of 23,476 trials

Pertuzumab and Trastuzumab as Neoadjuvant Treatment in Patients With HER2-Positive Breast Cancer

NCT01937117

This research is being done to determine if early changes on a type of imaging procedure called PET (Positron Emission Tomography) can predict which patients are most likely to respond to the combination of trastuzumab and pertuzumab when given prior to surgery.

Breast Cancer

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins88 participantsStarted Jan 2014

Birmingham, Alabama, United States • Washington D.C., District of Columbia, United States • Indianapolis, Indiana, United States +7 more locations

RECRUITINGEARLY Phase 1< 1 mile

A Study of Daratumumab and Dose-Adjusted EPOCH in Plasmablastic Lymphoma

NCT04139304

This feasibility trial studies how well daratumumab in combination with dose-adjusted etoposide, prednisone, vincristine sulfate, cyclophosphamide, and doxorubicin hydrochloride (DA-EPOCH) works in treating patients with newly diagnosed stage I-IV plasmablastic lymphoma. Plasmablastic lymphoma cells have high levels of a protein called CD38. Daratumumab is a monoclonal antibody that specifically targets CD38 expressing cells, and may help the body's immune system attack the cancer and interfere with the ability of cancer cells to grow and spread. Drugs used in chemotherapy, such as etoposide, prednisone, vincristine sulfate, cyclophosphamide, and doxorubicin hydrochloride, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving daratumumab may enhance the effectiveness of a standard chemotherapy (DA-EPOCH) in patients with plasmablastic lymphoma.

Plasmablastic LymphomaAnn Arbor Stage I Diffuse Large B-Cell LymphomaAnn Arbor Stage II Diffuse Large B-Cell Lymphoma+2 more

AIDS Malignancy Consortium15 participantsStarted May 2021

Miami, Florida, United States • Chicago, Illinois, United States • Baltimore, Maryland, United States +5 more locations

Pertuzumab and Trastuzumab as Neoadjuvant Treatment in Patients With HER2-Positive Breast Cancer

A Study of Daratumumab and Dose-Adjusted EPOCH in Plasmablastic Lymphoma

Find Trials by Condition in Baltimore

Using Technology to Track Pain and Pain-related Outcomes

Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer

Distal Radius Interventions for Fracture Treatment

Blood and Stool Sample Collection in Subjects With a Diagnosis of Colorectal Cancer or Colorectal Lesion: Act Fast

Vaginal Ecosystem and Network in the United States Study

Immune Checkpoint Inhibitor Nivolumab in People With Recurrent Select Rare CNS Cancers

A Study to Investigate LYL845 in Adults With Solid Tumors

Video-Based Patient Navigation to Support Cervical Cancer Screening Among Black Women

Beacon Sensors and Telerehabilitation for Low Vision

Study of ASN51 in Adults With Early Alzheimer's Disease

A Depression and Opioid Pragmatic Trial in Pharmacogenetics (Depression Trial)

A Phase III Trial of With Marizomib in Patients With Newly Diagnosed Glioblastoma

Study of Neoantigen-specific Adoptive T Cell Therapy for Newly Diagnosed MGMT Negative Glioblastoma Multiforme (GBM)

This Study Will Collect Clinical and Patient Reported Satisfaction Data From Males Requiring Urine Output Management Overnight in the Home Setting.

Safety, Tolerability & Potential Anti-cancer Activity of Increasing Doses of AZD5363 in Different Treatment Schedules

24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years Safety Long-term Treatment-free Follow-up

Pragmatic Randomised Trial of High Or Standard PHosphAte Targets in End-stage Kidney Disease (PHOSPHATE)

ACE2016 in Adult Subjects With Locally Advanced or Metastatic Solid Tumors Expressing Epidermal Growth Factor Receptor (EGFR)